Literature DB >> 16677659

Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns.

Virginia Garcia-Cañas1, Barry Lorbetskie, Michel Girard.   

Abstract

The characterization of influenza vaccine composition has been approached through a novel methodology suitable for routine analysis. It is based on a two-stage process involving an initial sample processing step followed by analysis by reversed-phase HPLC with UV detection. The sample processing involves an initial concentration step carried out in the presence of a combination of detergents and organic solvents to enhance solubilization and ultimately to provide adequate detection. Conditions that provided fast, reproducible and selective separations of vaccine constituents were investigated by reversed-phase HPLC. The use of non-porous silica stationary phases was found to minimize carry-over and non-specific adsorption observed with conventional columns. An evaluation of separation parameters, including mobile phase composition and column temperature, allowed optimization of the selectivity of the method. The optimized method was suitable for the characterization of processed monovalent preparations (containing influenza virus constituents from a single strain). In addition, it allowed the simultaneous detection of the three influenza subtypes in trivalent vaccines in a single analysis. Several influenza constituents were detected including nucleoprotein, the highly hydrophobic matrix protein and the primary surface antigen, haemagglutinin (HA).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677659     DOI: 10.1016/j.chroma.2006.04.003

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  15 in total

Review 1.  Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages.

Authors:  Petra Kramberger; Lidija Urbas; Aleš Štrancar
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.

Authors:  Mark W Lamere; Amy Moquin; F Eun-Hyung Lee; Ravi S Misra; Patrick J Blair; Laura Haynes; Troy D Randall; Frances E Lund; Denise A Kaminski
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

3.  Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine.

Authors:  Anastasija Shytuhina; Pavlo Pristatsky; Jian He; Danilo R Casimiro; Richard M Schwartz; Van M Hoang; Sha Ha
Journal:  J Chromatogr A       Date:  2014-06-19       Impact factor: 4.759

4.  Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

Authors:  A Ambati; L S V Boas; P Ljungman; L Testa; J F de Oliveira; M Aoun; V Colturato; M Maeurer; C M Machado
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

5.  Limited Tryptic Digestion-Isotope Dilution Mass Spectrometry (LTD-IDMS): A Reagent-Free Analytical Assay To Quantify Hemagglutinin of A(H5N1) Vaccine Material.

Authors:  Hans C Cooper; Yuhong Xie; Giuseppe Palladino; John R Barr; Ethan C Settembre; Yingxia Wen; Tracie L Williams
Journal:  Anal Chem       Date:  2020-08-12       Impact factor: 6.986

6.  Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.

Authors:  Masanori Terajima; John Cruz; Anita M Leporati; Laura Orphin; Jenny Aurielle B Babon; Mary Dawn T Co; Pamela Pazoles; Julie Jameson; Francis A Ennis
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

7.  In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

8.  Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.

Authors:  Douglas V Dolfi; Kathleen D Mansfield; Raj K Kurupati; Senthil Kannan; Susan A Doyle; Hildegund C J Ertl; Kenneth E Schmader; E John Wherry
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

9.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

Review 10.  Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.

Authors:  Christine M Thompson; Emma Petiot; Alexandre Lennaertz; Olivier Henry; Amine A Kamen
Journal:  Virol J       Date:  2013-05-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.